2019 Highlights

 

 

  • Revenues grew 7% this year, driven by growth in all core business areas
  • GAAP EPS increased 46%; Non-GAAP EPS increased 28% 
  • Biogen acquired commercialization rights to potential ophthalmology biosimilars of LUCENTIS® and EYLEA® in the U.S. and other major markets
  • FDA approved VUMERITY for the treatment of relapsing forms of MS
  • Biogen and its collaboration partner Eisai Co., Ltd. announced plans to submit a regulatory filing for aducanumab in Alzheimer’s disease based on a new analysis of a larger dataset from the Phase 3 EMERGE and ENGAGE studies
  • Biogen added 7 clinical programs to its pipeline
  • Biogen products treat ~34% of all treated MS patients globally
  • In Europe, 200,000 patients have been treated with a Biogen biosimilar and Biogen estimates that these biosimilars contributed ~ 1.8 billion euros in healthcare cost savings in Europe in 2019
  • After only 18 months on the market in the U.S., Germany, and France, Cleo and Aby now support more than 100,000 patients
  • 20% of annual revenue invested in R&D over the past decade


For more information, please review our GAAP to Non-GAAP Reconciliation

 

 

As Biogen grows, we remain committed to reducing our environmental footprint by eliminating harmful emissions and by minimizing resources used to manufacture our products. We are committed to: 

  • Continuing to match 100% of our electricity use (including power for electric vehicles) with electricity produced from renewable sources, our public commitment to the RE100 initiative since 2014. 
  • Reducing by 35% our absolute GHG footprint – across Scopes 1, 2 and 3 – by 2030 (compared to our 2013 footprint)
  • Assessing our water use and keeping use within our determined fair share (what the Center for Sustainable Organizations calls “fair, just and proportional share” of local water resources) 
  • Maintaining Zero Waste to Landfill status for our manufacturing facilities 
  • Continuing to leverage our 2020 intensity-based metrics for internal operational excellence and benchmarking
  • Engaging with our highest climate impacting suppliers to lower GHG emissions in our supply chain